Category Archives: Non-Surgical Procedure

Biotech, Diagnostics, Diseases, Healthcare, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Pharmaceuticals, Public Health, Society

New AI-powered predictive algorithm offers unprecedented accuracy in diagnosing NASH and liver fibrosis staging

Leave a comment

BOSTON, MA, United States, 18-Jul-2022 — /EPR HEALTHCARE NEWS/ — Metadeq Inc., a global NASH and metabolic diseases diagnostics company, today announced a breakthrough non-invasive blood test that utilizes two novel circulating proteins to accurately diagnose Non-alcoholic steato-hepatitis (NASH) and liver fibrosis, and can score the stages of both diseases, without the need for invasive liver biopsy. The study which details the new blood test – just revealed in Gut, a leading hepatology and gastroenterology journal published by BMJ – was led by King’s College London Professor Geltrude Mingrone, in collaboration with Metadeq.

Approximately one in four people worldwide, or approximately two billion people, have Non-alcoholic fatty liver disease (NAFLD) and therefore are at risk of developing NASH. NASH is the most severe form of NAFLD, a silent disease associated with fatty deposit build-up of the liver. NASH leads to advanced liver diseases such as liver fibrosis (scarring), cirrhosis, and liver cancer, and may ultimately result in death. The annual cost to the US healthcare system alone has been estimated to be over $100 billion per year.

Currently, the only way to diagnose NASH is through the standard of diagnosis, invasive liver biopsy, which is expensive and is associated with significant complications and discomfort. Until now, no reliable blood test has been developed for NASH, nor liver fibrosis. Most importantly, no available test can define the severity (stage), or monitor the progression, of either NASH or liver fibrosis.

Professor Geltrude Mingrone from the School of Cardiovascular and Metabolic Medicine & Sciences at King’s College London, who is one of the most widely cited and influential researchers globally for metabolic diseases and disorders, set out to discover a more accurate liquid biopsy test in support of patient care and in collaboration with Metadeq. The resulting study was published today in leading journal, Gut.

This study identified two novel protein biomarkers, PLIN2 and RAB14, to assist in the diagnosis of patients with NASH and/or liver fibrosis. The ability of these proteins to detect both diseases was tested in cohorts with either NASH and/or liver fibrosis that were confirmed with liver biopsy, the current standard of diagnosis.

“This blood test will allow researchers and clinicians to define the prevalence of NASH across populations, including children and adolescents, avoiding the need for invasive liver biopsy,” said Professor Mingrone. “Critically, it will allow care-givers to monitor the efficacy of NASH treatments over time, reducing screen failures and helping generate better drugs.”

“Since HEPAR-QTM is the only diagnostic modality that can diagnose NASH and fibrosis staging we expect it to be instrumental in the development of new therapeutics for the management of patients,” said Frank Jaksch, Chairman of Metadeq. “We believe that HEPAR-QTM will advance for the benefit of patients the problem of regular screening, that has resulted in late drug failures during clinical trials, since it is now possible to accurately measure the severity of disease in a non-invasive manner.”

 

The Metadeq predictive algorithm, which uses A.I., provided unprecedented sensitivity (88-95%), specificity (90-100%), and overall accuracy (92-93%) for NASH, and also has near-perfect sensitivity (99%-100%), specificity (90%-96%), and accuracy (98%-99%) for liver fibrosis.

The test results show that the proteins can provide rapid and cost-effective testing to combat the growing epidemic of NASH and liver fibrosis. This could be an invaluable tool in diagnosing and monitoring cases of liver diseases, allowing people to receive earlier treatment, from lifestyle adjustments to surgical and pharmacological interventions.

Currently no NASH drug has been approved by either the FDA or EMA, which may be a direct result of the lack of an accurate, reliable, and non-invasive test. More than 65% of patients who enroll in clinical trials for NASH-related therapies are found to be ineligible for the trial due to screen failure, which causes major monetary losses to companies developing and testing NASH drugs. The improved accuracy and ability to detect NASH staging will help in identifying and enrolling the appropriate people in clinical trials, speeding up the development of NASH drugs.

About Metadeq
Metadeq Corp. is a diagnostics company that provides innovative liquid biopsy solutions for liver and metabolic diseases. For the first time, Metadeq allows people to measure the whole spectrum of liver diseases – from NAFLD, to NASH, and liver fibrosis – with a blood test. www.metadeq.com

SOURCE: EuropaWire

Biotech, Doctors, Eye Care, Healthcare, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Ophthalmology

8-year follow up results revealed for the ELIOS® Excimer Laser Trabeculostomy procedure combined with cataract surgery

Leave a comment

LOS ANGELES, CA, United States, 17-Feb-2022 — /EPR HEALTHCARE NEWS/ — Elios Vision Inc. announced today 8-year follow up results of its novel ELIOS® Excimer Laser Trabeculostomy procedure combined with cataract surgery.

Key study findings:

  • 161 eyes of 128 patients with glaucoma or ocular hypertension and cataract received Phaco-ELIOS, and were followed over an 8-year period
  • Significant mean IOP reduction from 19.3 mmHg at baseline to 15.4 mmHg after 8 years of follow-up (p=0.0040)
  • Significant reduction in medication requirements
  • Only 3.7% of patients required secondary surgical glaucoma intervention during the 8-year follow-up period
  • No serious intra- or post-operative events were observed

“This large cohort study provides encouraging evidence that the ‘implant free’ Phaco-ELIOS procedure causes minimal trauma, appears to show lasting IOP control with no serious intra- or post-operative complications, and low rate of incisional secondary surgical intervention over a period of at least 8 years,” said Thomas W. Samuelson, MD, founding partner of Minnesota Eye Consultants and an Adjunct Professor of Ophthalmology at the University of Minnesota. Dr Samuelson added that, “it is encouraging for patients that the number of topical medications required to control IOP was reduced significantly up to 4 years and remained below baseline levels across the entire 8-year follow-up period.”

About the ELIOS procedure:

  • The ELIOS procedure creates ten ‘microchannels (210µm)’ in the trabecular meshwork using an excimer laser.
  • The microchannels facilitate aqueous outflow into Schlemm’s canal, the eyes natural outflow pathway, reducing IOP2 and preserving the integrity, structure, and function of the trabecular meshwork.
  • Combining ELIOS with phacoemulsification is an ‘implant free’ minimally invasive glaucoma procedure with a rapid learning curve for ophthalmic surgeons.
  • The ELIOS procedure is approved in Europe for use in adults with glaucoma, with or without cataract, and is undergoing clinical trials in the US under an investigational device exemption (IDE).
  • Data on the ELIOS procedure has been published in 12 clinical studies2 with over 850 eyes treated showing an IOP reduction of 20-40% from baseline, a significant reduction of medication for up to 4 years, and up to 81% of patients ‘medication free’ at 1 year,3 and a favorable safety profile.

Over the past decade minimally invasive glaucoma surgeries (MIGS) have transformed the treatment of mild to moderate glaucoma and are an attractive alternative to more invasive incisional procedures such as trabeculectomy and tube shunts. Despite the growing popularity of MIGS, combining cataract and glaucoma surgery is not yet the preferred choice by most surgeons.

This clinical study shows that the ELIOS procedure is attractive to all ophthalmic surgeons for patients with glaucoma that are not controlled by medications or SLT because it reduces IOP to mid-teens for at least 8 years, minimizes postop inflammation, avoids intraocular implants, has a favorable safety profile, with or without cataract surgery.

Why are these findings relevant?

  • In 2022 it is estimated that around 29 million people globally will undergo cataract removal and around 20% also have glaucoma or ocular hypertension4.
  • These findings demonstrate a sustained reduction of IOP that is longer than any other currently available MIGS procedure.
  • Routinely combining cataract and glaucoma treatment is appealing since it can reduce the undesirable burden and side effects of drops and it can avoid patients undergoing two separate surgical procedures which also is more efficient for healthcare systems.

SOURCE: EuropaWire

Alternative medicine, Health Products, Healthcare, Healthcare Solutions, Non-Surgical Procedure, Therapies

Curatronic Ltd. announces the new Ultra-Flash impulse PEMF device exceeding 1 Tesla

Leave a comment

Jerusalem, Israel, 2021-Jan-28 — /EPR HEALTHCARE NEWS/ — The brand-new Curatron Ultra-Flash impulse PEMF machine for instantaneous pain relief.

Curatronic Ltd. announces to have started taking orders for their brand-new Curatron Ultra-Flash device completing the Curatron line of pulsed electromagnetic field therapy devices.

Curatronic Ltd. has succeeded in developing a completely service free, ultra-high intensity impulse PEMF device. The Curatron Ultra-Flash ultra-high intensity PEMF pulses are electronically controlled by high voltage solid state semiconductor game changing technology, without any need for service as required for obsolete spark gap technology.

The new Curatron Ultra-Flash has 10 internal computer-controlled programs offering a wide choice for various treatment possibilities. These built-in programs offer superior flexibility, including for use as ringer and oscillating applications of impulse PEMF.

Curatronic offers a wide range of PEMF models to choose from, according to individual needs. A wealth of information can be found on their website, both extensive technical information as well as practical applications.

Ben Philipson, CEO of Curatronic Ltd. said, “The amazing results for instantaneous pain relief have been experienced by me personally! Now that we have completed our line of impulse PEMF devices the new Curatron Ultra-Flash device excels in the ability to generate pulsed magnetic field levels exceeding the 10,000 Gauss barrier making all PEMF spark gap devices on the market obsolete. The new Ultra-Flash system is geared towards use by medical professionals and we are looking forward to start soon shipping to customers who have taken advantage of the large pre-order discount we offer.”

Further information can be found on the Curatronic website www.curatronic.com

Curatronic is the leading innovator in Pulsed Electromagnetic Field therapy. Founded in 2000, the company has clearly established itself as the undisputed leader in the field of PEMF therapy devices in 99 countries around the world.

Via EPR Network
More Healthcare press releases

Diseases, Drugs, Gynecology, Health Products, Healthcare, Healthcare Products, Healthcare Solutions, Medicine, Neurology, Non-Surgical Procedure, Oncology, Pharmaceuticals

LIDBREE™ receives marketing authorization in the United Kingdom

Leave a comment

SANTA BARBARA, CALIF., U.S.A. / BUDAPEST / STOCKHOLM, 5-Aug-2020 — /EPR HEALTHCARE NEWS/ — Palette Life Sciences AB (‘Palette’) with Gedeon Richter Plc. (‘Richter’), today announced that as a part of a decentralised regulatory procedure including thirty European Union Economic Area member states, Palette and Richter received national marketing authorization for LIDBREE™ in the United Kingdom (UK). The product is a novel, proprietary thermo gelling intrauterine formulation that can provide significant pain relief during common gynecological procedures.

LIDBREE’s marketing authorization is based on compelling data from clinical trials and investigations of sensory innervation in the reproductive area. In a pivotal clinical trial, LIDBREE treatment was associated with a significant reduction of pain and discomfort in women undergoing gynecological interventions.¹

“Our research group has detected pain nerves superficially throughout the uterus, which enable the use of local pain relief in many gynecological procedures such as insertion of an intrauterine device and sampling biopsies from the cervix and/or from the uterus – procedures that are currently routinely performed today without pain relief. LIDBREE is a novel gel containing the local anesthetic lidocaine which adheres to the mucosal tissue upon application to provide excellent analgesic effect”, says Gunvor Ekman-Ordeberg, MD PhD Professor at Karolinska Institute and founder of the LIDBREE program. “The gratification of observing the culmination of over 40 years of research into clinical practice via a new, simple, and effective treatment is a great privilege to share with all of my colleagues.”

In October 2017, Richter and Palette signed an agreement to commercialise LIDBREE, a novel innovative proprietary pain relief pharmaceutical formulation, in Europe and in certain other markets.

“We are very pleased with the approval of LIDBREE in the UK, it is a great accomplishment from everyone involved.  This is an important milestone and allows us to address a significant unmet medical need in women’s health. We look forward to supporting LIDBREE’s product launch through our partner Gedeon Richter and pursuing additional markets, such as the U.S., in collaboration with future regional partners.” says Helena Jansson, Managing Director at Palette Life Sciences AB.

“We’ve been expecting this regulatory development and we are looking forward to successfully introduce LIDBREE to all of the territories covered by our agreement in order to further improve the quality of life of women experiencing pain during their gynaecological interventions,” stated Tibor Horváth, Commercial Director of Gedeon Richter Plc.

SOURCE: EuropaWire

Biotech, Cancer, Diseases, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Oncology

First Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany done by Dr. Lutz-Hendrik Holle

Leave a comment

HANAU, Germany, 4-Oct-2019 — /EPR HEALTHCARE NEWS/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that Dr. Lutz-Hendrik Holle, Medical Director of the interregional professional association for nuclear medicine in Hanau, has accomplished the first Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany. This state-of-the-art technology of local radionuclide therapy offers a painless and non-invasive treatment option for patients with basal cell carcinoma and squamous cell carcinoma (BCC and SCC) and the interregional professional association for nuclear medicine Hanau is the first center in Germany that offers the Rhenium-SCT®.

With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods. The key argument for the expansion of the spectrum was that the Rhenium-SCT® is a new, painless and highly efficient treatment option that also delivers excellent cosmetic results. Besides being a painless alternative to other procedures, the Rhenium-SCT® also allows the treatment of numerous NMSC lesions consecutively in a single session, which was already realized during the first treatment in Hanau. This has also attracted international attention so that an American patient travelled to Hanau for the treatment.

“This therapy is particularly suitable for tumor localizations where good cosmetic results are to be achieved. The fact that the treatment is completely painless and can be performed in just one session is a great advantage”, says Dr. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.

“We are very happy and proud to be able to offer our revolutionary treatment to patients in Germany now. The interregional professional association of nuclear medicine in Hanau is an excellent partner for NMSC patients in the fight against NMSC”, said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “Unfortunately, Germany is one of the countries that has experienced a drastic increase in newly diagnosed NMSC cases in recent years. Our highly qualified team strives to provide physicians and patients with a non-invasive and affordable solution to treat NMSC, while focusing on the needs of the patient.”

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In certain analyzed areas of Germany there was an increase in the incidence between the year 2005 and the year 2014 by about 30%1. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients’ lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application in most of the cases, applied in one single session with excellent aesthetic outcomes.

Via EPR Network
More Healthcare press releases

Biotech, Cancer, Diseases, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Oncology

2019 Red Herring North America Top 100 Winner: New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients

Leave a comment

Pasadena, CA, U.S.A., 6-Jul-2019 — /EPR HEALTHCARE NEWS/ — OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that it was honored as a Red Herring Top 100 North America Award winner recognizing the continent’s most exciting and innovative private technology companies. After being recognized with the Red Herring Top 100 Europe Award earlier this year, this is now the second recognition obtained by Red Herring.

The winners, celebrated at a special awards ceremony at the Westin Pasadena hotel, have been chosen from thousands of entrants, whittled down to hundreds making the trip to California. The ceremony, led by Red Herring chairman Alex Vieux, was preceded by two days of keynote speeches, discussions and finalist presentations.

Companies were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy, and market penetration. Winners ran the gamut of verticals, from FinTech and Marketing to Security, IoT, and many more industries.

Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades. It gives them the ability to see through the industry’s hype to pick firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.

“2019’s crop of Top 100 winners has been among our most intriguing yet,” said Vieux. “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here in California, which is in many ways the heartland of the industry, has been a thrilling experience.”

“What has excited me most is to see so many people forging niches in high-tech and cutting edge sectors,” added Vieux. “Some of the technical wizardry and first-rate business models showcased here at the conference has been fantastic to learn about. We believe OncoBeta® embodies the drive, skill and passion on which tech thrives. OncoBeta® should be proud of its achievement – the competition was incredibly strong.”

“Being named as one of the Red Herring’s Top 100 North America award winner in addition to the Top 100 Europe is a great honor for us.” states Shannon D. Brown III, CEO of OncoBeta®. “The spirit of the award aligns perfectly with our team’s mission in the fight against non-melanocytic skin cancer (NMSC) with the Rhenium-SCT®.”

The complete list of the 2019 Red Herring North America Top 100 Winners can be found here in alphabetical order: https://www.redherring.com/2019-rhna-top100-winners/

Red Herring’s press release is available online at https://www.redherring.com/red-herring-2019-top-100-north-america-winners-press-release/

SOURCE: EuropaWire

Biotech, Cancer, Diseases, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Oncology

The interregional professional association for nuclear medicine in Hanau has become the first treatment center in Germany to offer the Rhenium-SCT® (SCT= Skin Cancer Therapy)

Leave a comment

GARCHING N. MUNICH, Germany, 13-May-2019 — /EPR HEALTHCARE NEWS/ — OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that the interregional professional association for nuclear medicine in Hanau now offers the Rhenium-SCT ® (SCT= Skin Cancer Therapy) as the first treatment center in Germany.

With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods which are state-of the art in science and technology.

“Offering NMSC skin cancer patients a highly efficient, painless, innovative therapy with excellent aesthetic results was the driving reason to establish this treatment method in our clinic,” says Dr. med. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.

“We are delighted that our innovative skin cancer therapy Rhenium-SCT® is now being offered by the Nuclear Medicine in Hanau and we are looking forward to this collaboration”, states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “For us, this is an important step to offer the treatment method in addition to Italy, South Africa and Australia now also in Germany. In order to provide our treatment to as many skin cancer patients as possible, it is of course our goal to offer the availability of the therapy nationwide in Germany in the future.”

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In Germany the number of newly diagnosed patients is about 200,000 annually and it is assumed that this number increases within the next years. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients’ lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.

If interested, patients and doctors can either contact the interregional professional association for nuclear medicine in Hanau directly or OncoBeta® GmbH.

SOURCE: EuropaWire

Biotech, Cancer, Diseases, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Oncology

University of Pretoria Prof. Mike Sathekge is First in South Africa to Treat Non-Melanocytic Skin #Cancer Patients with Rhenium-SCT®

Leave a comment

Garching n. Munich, Germany, 26-Nov-2018 — /EPR HEALTHCARE NEWS/ — OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today that Prof. Mike Sathekge from the University of Pretoria, Steve Biko Academic Hospital Nuclear Medical department and his clinical team has treated the first non-melanocytic skin cancer patients in South Africa with the innovative Rhenium-SCT® skin cancer treatment System. This next-generation radionuclide therapy technology applied by the nuclear medicine physician offers a new singles session, painless treatment for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs).

The global incidence of non-melanoma skin cancers has drastically increased over the few past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Approximately 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas with South Africa having one of the highest incidence rates in the world.

Prof. Mike Sathekge and his team at the University of Pretoria, Steve Biko Academic Hospital are focused on providing patients with personalized care using state-of-the-art technology that can deliver high-precision therapy and diagnostics with minimal side effects. The specialized team of experts in the nuclear medicine and medical physics, work closely with other disciplines within the university hospital, referring physicians, and other institutions, to ensure patients receive the best possible treatment for their specific type of cancer.

Martin Magwaza, CEO of Tautomer (PTY) LTD Oncobeta®’s distribution partner for the Rhenium-SCT® in Africa, is dedicated to providing South Africans with new innovative and effective therapies across the continent, coordinating with representatives from all levels of government and state for the health care landscape.

“The start of the Rhenium-SCT® in South Africa is a significant milestone in the international expansion of our ground-breaking treatment for BCCs and SCCs.,” said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “Our vision of bringing a revolutionary affordable skin cancer therapy to physicians and patients all over the world has come one step closer today”.

SOURCE: EuropaWire

Alternative medicine, Disorders, Healthcare, Healthcare Products, Healthcare Services, Healthcare Solutions, Non-Surgical Procedure, Therapies, Urology

Study published in World Journal of Urology confirms Fotona SMOOTH® laser technology is a safe, effective & minimally-invasive solution for stress and mixed urinary incontinence

Leave a comment

LJUBLJANA, Slovenia, 21-Sep-2018 — /EPR HEALTHCARE NEWS/ — The latest study published in the World Journal of Urology (Comparison between erbium‑doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence – https://doi.org/10.1007/s00345-018-2445-x) provides further confirmation that Fotona SMOOTH® laser technology is a safe, effective and minimally-invasive solution for stress and mixed urinary incontinence (SUI and MUI). The article, written by Dr. Nobuo Okui, compares Fotona’s minimally invasive IncontiLase® Er:YAG laser therapy with the more conventional TVT and TOT surgical sling procedures.

Asian Study Confirms Favorable Results of Fotona SMOOTH® Laser Therapy for Urinary Incontinence

In the study performed by Dr. Okui, 50 Japanese women were treated either surgically (tension-free vaginal tape – TVT or transobturator tape – TOT) or with a Fotona laser. The 1-h pad test, ICIQ-SF, and overactive bladder-symptom score were used to assess the patients before and 12 months after treatment. Laser therapy was performed by first applying a local anesthetic to the vaginal wall and then inserting a probe into the vagina. Laser irradiation was performed for 20 min with an Er:YAG wavelength of 2940 nm (Dynamis XS, Fotona) for a total of three treatments (alternating every month). Results of the 1-h pad test and ICIQ-SF showed comparable improvements in SUI in the sling and laser therapy groups, while some of the patients with MUI in the TVT and TOT groups showed exacerbation. In conclusion, the TVT and TOT procedures and the laser therapy are comparable for SUI; however, laser therapy is superior in terms of MUI and complications. The study thus once again confirms the safety and efficacy of Fotona SMOOTH® laser therapy for urinary incontinence.

Urinary Incontinence Treatment Options

Conventional treatment options for urinary incontinence are surgical, and include TVT or TOT sling procedures, which involve inserting a synthetic material. Problems often arise with artificial meshes that require new treatment methods. With the Fotona SMOOTH® Er:YAG laser thermotherapy (also known as IncontiLase®), the goal is to provide a minimally invasive therapy based on vaginal collagen hyperthermia followed by collagen remodeling and new collagen synthesis, which results in overall regeneration of aged or stressed vaginal tissues and subsequently greater support to the bladder.

Unique Fotona SMOOTH® Technology for Maximum Safety

Patient safety is the primary concern and, for this reason, the patented Fotona SMOOTH® technology holds a very unique position within the spectrum of gynecological treatment options. It is a non-surgical procedure (no incisions) and without implants or appliances. The Fotona SMOOTH® method of dual-tissue regeneration is completely non-ablative and therefore minimally invasive to the vaginal wall. The treatment involves an additional superficial heat-shocking mechanism of tissue regeneration, and a unique self-regulating safety feature. These dual-tissue regeneration characteristics of the Fotona SMOOTH® Er:YAG laser allow for an exceptionally high degree of safety and efficacy in thermotherapy of the vaginal wall. This is what makes Fotona SMOOTH® a significantly safer alternative to many widely used and more-invasive procedures.

Evidence-Based Laser Medicine

Over the past few years numerous (over 35) other studies on Fotona SMOOTH® laser therapy have been published by distinguished gynecologists from around the globe in some of the most trusted and renowned international scientific journals, all with favorable results (https://www.laserandhealthacademy.com/en/practitioners/recommended-reading/gynecology/). One such noteworthy clinical paper published in March 2018 by Dr. Adolf Lukanovic and Dr. Mija Blaganje is the first randomized controlled trial study (on 114 premenopausal parous women) to evaluate the efficacy and safety of non-ablative Er:YAG laser therapy as an alternative non-invasive treatment of SUI and the improvement of sexual gratification (published in the European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018 (224): 153-158). The results from this study indicate that a single session of IncontiLase® treatment improves the impact of SUI symptoms on quality of life and sexual function in premenopausal parous women significantly better than placebo.

In another Asian study, Dr. Yi-Wen Tien et al. from the Chang-Hua Hospital in Taiwan examined the effects of laser treatment for female SUI on pad weight, urodynamics, and sexual function in 35 women (published in the International Urogynecology Journal. 2017; 28(3): 469-476). The study reveals that the effect of IncontiLase® treatment for mild SUI was moderate at the 6-month follow-up. Moreover, it improved LUTS, quality of life, and the sexual function of both partners. The authors conclude that the IntimaLase® procedure is very effective in the treatment of SUI and is not associated with any severe adverse effects.

Similarly, Dr. Yi-Hao Lin et al. from the Chang Gung Memorial Hospital in Taiwan obtained favorable results. Their study investigated the effects of non-ablative laser treatment on overactive bladder (OAB) syndromes, SUI and sexual function in 30 women with urodynamic stress incontinence (published in the Taiwanese Journal of Obstetrics & Gynecology. 2017 (56): 815-820). The results showed that IncontiLase® treatment can resolve SUI and coexistent OAB symptoms three months after therapy, while repeated laser therapy may be necessary after six months. The results also revealed that sexual gratification improved, while no major adverse effects were noticed.

The quantity and quality of the studies performed with Fotona SMOOTH® laser therapy is such that Fotona’s Dynamis has been cleared in the European Union for SUI (IncontiLase®), vaginal laxity – vaginal relaxation syndrome (IntimaLase®), genitourinary syndrome of menopause – GSM (RenovaLase®) and pelvic organ prolapse (ProlapLase®), giving women the option to choose a safer and less-invasive treatment alternative. In Asia, the Taiwan Food and Drug Administration has already cleared Fotona Dynamis for mild to moderate SUI, and the Singapore Health Sciences Authority has cleared the Dynamis for the treatment of SUI and GSM.

SOURCE: EuropaWire

Business of Medicine, Cancer, Diagnostics, Diseases, Health 2.0, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Healthcare Software, Healthcare Solutions, Non-Surgical Procedure, Oncology, Therapies

Multispectral Optoacoustic Tomography (MSOT) can now more reliably detect early stages of inflammation

Leave a comment

GERMANY, Mar-30-2017 — /EPR HEALTHCARE NEWS/ — Ulcerative colitis and Crohn’s disease are the most common inflammatory bowel diseases (IBD). Globally, more than 4 million people suffer from recurring inflammation of the intestinal mucosa. To date, non-invasive methods have not been able to detect these forms of IBD reliably. Researchers at the University Hospital Erlangen (Germany) have now shown for the first time how Multispectral Optoacoustic Tomography (MSOT) can more reliably detect early stages of inflammation when compared with other non-invasive diagnostic methods. These results have recently been published in the New England Journal of Medicine.

Evaluating the inflammatory activity of the intestines early and accurately helps to prevent complications associated with IBD and guide an optimal therapy regime. Currently, doctors frequently rely on an invasive endoscopy procedure to assess the intestinal mucosa of patients with IBD. Additionally, non-invasive imaging methods are increasingly used in the clinic. For example, ultrasound allows clinicians to examine the structure, thickness and blood perfusion of the intestinal wall with changes in perfusion patterns indicating an onset of inflammation.

“With the MSOT procedure, we additionally use laser light, by which we can detect inflammation earlier than previously possible with ultrasound”, explains Prof. Dr. Maximilian Waldner, Professor at the University Hospital Erlangen. “The earlier we detect signs of an upcoming flare – i.e., a change in blood content – the quicker we can react and start a preventive treatment”. The MSOT technology was developed by iThera Medical in Munich, and was first used on IBD patients last year.

The researchers of the University Hospital Erlangen have recently published their results in the renowned New England Journal of Medicine. “We examined 108 patients with Crohn’s disease using the MSOT technology and compared the results to established non-invasive diagnostic procedures as well as endoscopy and histology”, says Prof. Waldner. “We were able to demonstrate that hemoglobin values in the tissue measured with MSOT indicate very accurately the inflammatory activity in the intestines. The method appears to be superior to other non-invasive procedures, as MSOT for the first time was able to detect even low levels of inflammation without having to perform endoscopy”.

Dr. Ferdinand Knieling, a physician at the University Hospital Erlangen, adds: “We are hoping that this principle can be applied to many applications and, in particular, also be used to enable safe evaluations of children and adolescents. With this new examination method, many of the currently invasive procedures might become obsolete.”

In optoacoustic imaging, the physician scans the intestines transabdominally through the skin, applying pulsed laser light in the near-infrared region. The energy of the light absorbed in tissue is converted into acoustic signals which are then acquired by an ultrasound detector. Christian Wiest, CEO of iThera Medical, comments: “MSOT is a new diagnostic imaging modality that can detect changes in tissue composition associated with a variety of diseases, without the use of contrast agents. The technology has already been applied in other clinical feasibility studies, e.g. for the detection of melanoma metastasis in sentinel lymph nodes or for the assessment of suspicious breast lesions”.

The results of the IBD study at the University Hospital Erlangen were published on March 30th 2017 in the New England Journal of Medicine (Volume 376, Issue 13, pg.1292-1294).

SOURCE: EuropaWire

Alternative medicine, Diseases, Disorders, Doctors, Healthcare, Healthcare Services, Neurology, Non-Surgical Procedure, Therapies

TESTmyBRAIN opens its first center of Functional Neurology in Europe

Leave a comment

GENEVA, 2016-Jun-8 — /EPR Healthcare News/ — TESTmyBRAIN (Switzerland) has opened its first center of Functional Neurology in Europe. This non-invasive therapy (no medication, no surgery) coming from the United States helps patients suffering from migraines, concussions, strokes, AD/HD, Parkinson disease, Alzheimer, … all disorders related to the brain and the central nervous system.

This innovative therapy combines several approaches and relies mainly over 3 decades of research on the eye-movements to diagnose and treat. Completely adopted and established in the United States, this therapy is almost unknown in Europe.

This is the reason why TESTmyBRAIN Switzerland is happy to bring the American experts to Europe to teach other doctors and to help patients differently with their pain.

SOURCE: EuropaWire

Alternative medicine, Health Products, Healthcare, Medicine, Non-Surgical Procedure, Reproductive Medicine

A New natural treatment for female infertility caused by tubal blockage and hydrosalpinx helps women conceive without painful surgery

Leave a comment

Tubal blockage caused by inflammation, and hydrosalpinx, which are commonly used to be treated with surgery, such as laparoscopy, now can be cured with a new natural treatment – Fuyan pill – a herbal medicine invented by Dr. Lee who comes from Wuhan Dr. lee’s TCM clinic. It gives the hope for the female infertility to be conceived successfully.

Wuhan, CHINA, May 04, 2015 — /EPR HEALTHCARE NEWS/ — The Fuyan pill, based on ancient Chinese formulas for gynecological inflammations, which lasts for over 5000 years, is made from natural pure herbs without any chemical composition. According to the data from Wuhan Dr. Lee’s TCM Clinic, this natural herbal formula has cured hundreds of thousands women infertility who had suffered from tubal blockage led by inflammation, hydrosalpinx and their complications.

The inventor of this herbal medicine, Dr. Lee introduces: “This herbal medicine can cure inflammatory tubal blockage and hydropsalpinx without any other unpleasant procedures.” “Even for those had tried IVF to conceive unsuccessfully. Fuyan Pill also works on some of them when they try it as their last shot. According to our clinical cases, these diseases are commonly cured after three to four months medication. ” Dr. Lee says

Ada who had suffered from inflammatory tubal blockage for more than 3 years told us. “I had never been imaging that Fuyan Pill could work so fast that I got pregnant in third month medication. Well to be frank, taking the pills are not very pleasant experience, but doing these for 4 months is really worth my effort. I have been under a lot of pressure not being able to conceive, and I sometimes have even doubted the efficiency of this herb, because I feel nothing during the medication. However everything has changed after I got my ultrasound report after I finish 3 months pills. Dr. Lee has suggested me to take one more months pills after that in case it recurs and I have done as she’s recommended. The pill has made a huge difference and I am so grateful for what Dr. Lee has done.”

Chinese medicine owns outstanding sterilizing power to treat tubal blockage, especially, has special effects on hydrosalpinx. The pill can effectively cure these kinds of diseases without any side effects. It also contains prescription to clear away heat and toxic material, promote blood circulation, dissolve stasis, unblock the fallopian tubes and drive away the hydrops completely, which help to retrieve fallopian tube movements and clear the tube for the fertilization of eggs. Thus it could help patients conceive naturally without surgery. Patients could try pregnant after taking the medicine for 3 to 4 months.

Dr. Lee says, “Fuyan Pill has been widely used in our own clinic in China, the clinic states also show that it has been effectively cured women with inflammatory tube blockage and hydrosalpinx who don’t want to undergo surgery. It also has no postoperative problems, this really attractive for many women. So there are increasing number of women have benefitted from this magical medicine recent years. We really hope it could also help women infertility caused by inflammatory tubal blockage and hydrosalpinx from all over the world.”

About Dr. Lee Xiaoping and the herbal medicine:
Dr. Lee Xiaoping graduated from Hubei College of Traditional Chinese Medicine, China. She qualified as an herbalist 30 years ago and is a highly experienced medical professional. She specializes in the field of male and female reproductive and urinary system diseases. She has devoted 30 years to her clinic and worked on the formula of Fuyan Pill for years. The medicine has proven to be effective on treating tubal conditions. The formula is patented by SIPO (State Intellectual Property Office of the P.R.C) with the application number 201110031968.

For more details about DR. Lee and Wuhan Dr. Lee’s TCM Clinic, please kindly view http://www.drleetcmclinic.com/

Contact-Details:
Wuhan Dr. Lee
Telephone: +86-027-87105085
Email: herbalistlee@yahoo.com, wuhandrlee@hotmail.com
Website: http://global.fuyanpills.com/index.html

Via EPR Network
More Healthcare press releases

Fitness, Healthcare, Healthcare Services, Medical Tourism, Non-Surgical Procedure, Public Health, Society, Therapies

Heavenly Spa Set to Follow Up the Success of their ‘Colonic Irrigation’ YouTube Video with a New Video Promoting their London Spa

Leave a comment

Having already found success with their ‘Colonic Irrigation London & Colonic Irrigation Information’ YouTube Video, Heavenly Spa are Soon to Launch a New Video Showing the Many Other Treatments that their Central London Spa Offers.

Nine months after their colonic irrigation video’s release on YouTube and over 8,000 views later, Heavenly Spa are in the later stages of production for a new video that showcases their spa and the many treatments that they offer. Their idyllic spa is located just a short two minute walk from Paddington Underground Station in London, tucked away in a quiet, discreet mews.

“We offer our clients the ultimate in relaxation and rejuvenation.” says Heavenly Spa owner Marlin Armstrong. “We are in such a great location what with Paddington being just two minutes away, but the lovely mews that we’re in allows our clients to be transported away from the hustle and bustle of London and into our calming retreat – we even have a dedicated relaxation room to allow our clients to unwind before and after their treatments.”

The spa and its fully trained beauty therapists are the leaders in colonic irrigation. “The spa is built on the ethos of “beauty starts from within” and our colonic treatment promotes complete well-being from the inside out” explains Marlin. Their treatment comes recommended by Elle Magazine who said their colonic hydrotherapy treatment was “A whole lot easier than previous experiences.”

Priding themselves on providing the client with the most discreet, unobtrusive and comfortable colonic irrigation possible, Heavenly Spa uses the most advanced and medically approved colonics system. “Once clients understand the process, they are able to relax and enjoy their colonic.” says Marlin.

Colonic hydrotherapy works by using warm, filtered water to loosen faecal matter and stimulate its release. “This process allows the bowel to hydrate, cleanse, detoxify and tone internally.” explains Marlin. “A colonic irrigation can result in reduced bloating and a stronger immune system. It can also be highly beneficial for those suffering with constipation and irritable bowel syndrome – though we do recommend a course of treatment if this is case.”

Their clients can either opt for a one off treatment, a course of treatments or colonic irrigation can form part of a bespoke well-being package, specifically designed to achieve clear, long lasting results for the client.

Heavenly Spa has many relaxation therapies and facilities, such as an exercise pool and gym, an infra red deep-heat absorption sauna and massage treatments. “Upon speaking with our clients and gauging what results they want, we can design a tailor-made treatment plan to get them to their goal and achieve long lasting results.” says Marlin.

With a new online video in the pipeline, Marlin hopes that viewers will be able to get a sense of their blissful spa. “Heavenly Spa is specially designed to amplify natural daylight and it is filled with purified air. Our colonic irrigation video does show our spa and its natural architecture and relaxing vibe. It has been such a success so we wanted to release another video that goes into more depth about the other treatments and therapies we offer here.”

To see their colonic irrigation video, follow this link https://www.youtube.com/watch?v=t-U9xGepDJ8 or visit their website at http://www.heavenlyspa.co.uk.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Non-Surgical Procedure, Plastic Surgery, Society

Varicose Vein Treatment Offers Multi-Million Savings For Hard-Pressed NHS

Leave a comment

As the pressure on the NHS to find efficiency savings increases, several trusts are looking to adopt a pioneering approach to varicose vein treatment that saves resources, while improving patient outcomes.

If adopted by all hospitals, The VNUS Closure procedure for the treatment of varicose veins, endorsed by the NHS National Innovation Centre, could save the health service around £17million.

The major benefits for the NHS lie in the fact that this procedure is much less resource-intensive than surgery. Conventional varicose vein stripping is a common operation, and one that takes up a great deal of operating theatre time.

The VNUS Closure procedure, however, can be carried-out in a treatment room, freeing up surgical theatres, enabling the NHS to treat other serious conditions more quickly and so reduce waiting-times.

It is said that as many as one in three adults in the UK suffers from venous reflux or varicose veins at some point in their life, and varicose vein treatment is one of the most common hospital procedures.

Almost 90,000 varicose vein operations were carried-out by the NHS in 2005-06, while approximately 20,000 similar operations were conducted privately, producing a total of around 110,000 procedures per year.

As long ago as 1999, a study conducted by the University of Edinburgh, put the total cost to the NHS at between £400m and £600m.

It is difficult to compare accurately the direct costs of conventional surgery and VNUS Closure. However, as the procedure is carried out under local anaesthetic without an overnight stay, and performed with minimal staff in a simple treatment room, this technique offers significant benefits for the NHS.

Cost savings are estimated to be between £40 and £450 per patient, depending on whether or not the patient requires an overnight stay.

The VNUS Closure is also expected to bring benefits to the wider economy, with patients being able to return to work almost immediately after their procedure with little or no pain.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Non-Surgical Procedure, Plastic Surgery, Society

Pioneering Varicose Vein Treatment Gets Patients Back On Their Feet In No Time

Leave a comment

Varicose veins can be painful and unsightly, with treatment often meaning surgery under general anaesthetic and a long recovery period.

While the traditional surgical approach has meant painful vein stripping, many UK hospitals now offer minimally invasive catheter technology that enables even severe varicose veins to be successfully treated in an outpatient setting, under a local anaesthetic.

Taking just a few minutes, a device is inserted into the diseased vein, where a catheter or fibre delivers either radio frequency or laser energy to heat and seal the vessel. The technique is extremely successful and far less painful and traumatic to the patient than vein stripping.

Endovenous laser (EVL) devices utilise an optical fibre to deliver extremely high levels of heat – over 700 degrees centigrade – that boils the blood in the vein to create a clotting effect that seals the vein as the device is withdrawn.

Radiofrequency devices operate at far lower temperatures to heat and shrink the vein walls, limiting the impact on surrounding tissues and, according to a clinical study, causing significantly less pain and bruising than laser.

Vascular surgeons using the VNUS® ClosureFAST™ catheter, the only radiofrequency device on the market today for the treatment of venous reflux, report that most patients return to normal activity almost immediately following the procedure, with little or no post-operative pain.

Radiofrequency endovenous ablation is a minimally invasive procedure for treating venous reflux disease, using Radiofrequency to heat and seal diseased veins, thereby reducing or eliminating existing varicose veins.

With the VNUS® ClosureFAST™ catheter, radiofrequency energy is delivered through a heating element seven centimetres long, to heat the collagen within the vein walls and cause the shrinkage and collapse of the vessel.

The closure procedure is generally performed using local anaesthesia, typically in a hospital theatre or an outpatient facility.

A ClosureFASTâ„¢ catheter is inserted into the vein through a tiny incision below the knee. Guided by ultrasound imaging, the vascular surgeon treats each 7cm segment of vein with a 20-second burst of radiofrequency energy, causing the vessel to shrink around the catheter.

The vascular surgeon withdraws the catheter, treating each segment until the entire vessel has been sealed. On average, 45cm of vein can be treated in three to five minutes.

In a clinical trial comparing Closure to laser, patients treated with Closure experienced less pain, less bruising and fewer complications, while a
one-year clinical data has shown the ClosureFASTâ„¢ catheter to be more than 97.4% effective in preventing reflux recurrence.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Non-Surgical Procedure, Plastic Surgery, Society

Revolutionary Treatment Could Mean End For Varicose Vein Surgery

Leave a comment

A revolutionary new treatment for varicose veins is proving a successful alternative to surgery.

The VNUS ClosureFast catheter is a minimally invasive alternative treatment, which doctors claim, results in less pain and bruising than traditional vein stripping surgery.

Using the Closure system, doctors close the diseased veins by inserting the closure catheter into a vein and heating the vein wall using temperature-controlled RF energy. As it is catheter-based, it results in little to no scarring.

Heating the vein wall causes collagen in the wall to shrink and the vein to close. After the vein is sealed shut, blood then naturally reroutes to healthy veins.

Dr Thomas Proebstle, a dermatologist and expert in venous diseases, said: “Beauty treatments and aesthetic surgery is on the increase all over the world. Quite often, this is associated with risky procedures, some pain and lengthy courses of wound healing.

“With this new, less-invasive approach, the procedure is much more gentle and smoother. The risks are much lower and the pain is kept to a low level, plus it can be administered under local anesthetic.”

Dr Proebstle, who is Professor for Dermatology at University of Pecs in Hungary, added: “Obviously this type of treatment does not need to be performed in a theatre or hospital, which improves its cost-effectiveness. It can easily be performed in an outpatient setting with the right medical facilities.”

The results of a recently published three-year-study carried out at eight european centres, which involved 225 outpatients, showed a huge success rate for the treatment.

The study showed that between 12 and 24 months after the treatment, 96.4 per cent of patients reported they had no pain. After 24 months, that number had increased to more than 99 per cent.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Non-Surgical Procedure, Plastic Surgery, Society

VNUS Closure Procedure to save NHS ‘millions’

Leave a comment

As the NHS faces budget restrictions, a non-surgical treatment for varicose veins (http://www.vnus.co.uk) has the potential to save the NHS millions of pounds.

Government ministers have promised that frontline services will be protected from cuts, but the NHS Confederation believes that this is unlikely to be achieved given the scale of the savings needed.

It estimates that the health service will have to make savings of £20bn over the next four years, as demand for healthcare continues to grow but increases in funding come to an end.

It is estimated that the VNUS Closure Procedure could potentially save the NHS £17 million, while helping 7,000 patients avoid further treatment due to failed alternative methods.

“This procedure has enabled many NHS Trusts throughout the country to take a very common operation out of the operating theatre and into treatment rooms, helping to free-up theatres for other cases,” said, Michael Branagan-Harris, Group Manager for NHS Medical Device Market Access For Innovative Medical Devices.

The VNUS Closure Procedure involves a hospital stay of just a couple of hours, treatment under local, rather than general anaesthetic, and a much faster recovery time.

Most patients undergoing a VNUS procedure walk out of the treatment room unaided and are usually able to return home and resume work within a day, with little or no pain.

For the NHS, the procedure is also much less resource-intensive than surgery. Conventional varicose vein stripping is a common operation, taking-up a great deal of operating theatre time.

For same costs, a further 25,000 patients could be treated earlier and avoid pain, or discomfort.

As the VNUS Closure procedure can be carried-out in a treatment room, it has the potential to free-up theatre-time, enabling the NHS to treat other serious conditions more quickly and so reduce waiting-times.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Liposuction, Non-Surgical Procedure, Obesity, Plastic Surgery, Society, Weight loss

Chubby Celebs Make Obesity The “Norm”

Stick thin celebrities have long been held responsible for the pressure on ordinary people to lose weight – now it would seem the tables have turned and fat celebrities are being blamed for the rising obesity epidemic.

Experts say that tubby celebs such as “Gavin and Stacey’s” James Corden and Ruth Jones are making obesity more socially acceptable and “normal”.

The profile of “larger” celebs has considerably risen over the years, with names such as Dawn French, Jonny Vegas, Peter Kay and of course Fern Britton (who has now lost her weight), appearing on our screens.

A recent report revealed that 23 per cent of Brits are now classed as obese compared to just 11 per cent 10 years ago.

More than 2,000 people took part in a nationwide survey in which researchers found that 17 per cent of obese people refuse to consider taking action to lose weight, whether via surgery or extreme diet regimes.

Weight loss doesn’t have to revolve around fad diets and excruciating exercise regimes though. The Hospital Group, one of the country’s leading obesity and cosmetic surgery providers, offers a wide range of obesity treatments including gastric band and body shaping treatments including liposuction and tummy tuck.

Last year The Hospital Group saw a staggering 73 per cent increase in the number of enquires made regarding weight loss surgery, making them the largest obesity surgery provider in the UK.

Since The Hospital Group was established in 1992, it has grown from a small pharmaceutical company to one of the UK’s foremost weight loss surgery providers.

For further information of The Hospital Group’s range of weight loss procedures, surgery-seekers should visit the website www.thehospitalgroup.org or call our patient care coordinators on 0845 762 6727.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Non-Surgical Procedure, Plastic Surgery, Society

Thousands Of Brits Undergo BOTOX® Treatment Every Year To Reduce The Appearance Of Laughter Lines And Furrowed Brows

However scientists have discovered another use for the anti-wrinkle treatment. Not only can it be used to reduce the effects of ageing and stop hyperhidrosis (excessive sweating), but BOTOX® can now actually improve your mood as well.

Researchers at Cardiff University investigated the effects of cosmetic treatments on the mood of 25 volunteers.

Out of the group a number of them underwent BOTOX® whilst others had laser surgery, cosmetic peels and numerous other treatments designed to make the skin look younger. All of the groups felt that their treatment was particularly effective, but those given BOTOX® said they felt much happier.

Researchers believe that our expressions affect our mood, so when we wrinkle our brows when annoyed it only reinforces our irritation.

Therefore by stopping the face from frowning, BOTOX® actually makes patients feel happier.

David Ross, chief executive of The Hospital Group, said: “Despite the recession, our clinics have reported a surge in the number of BOTOX® treatments conducted across the country.

“For many years we have noticed the positive effect the treatment has had not only on our patient’s appearance, but also their mood. Patients leave our clinics in high spirits which we feel contributes to their numerous return visits.”

The Hospital Group, one of the country’s leading cosmetic surgeries, provides a vast number of age preventative treatments across its 19 clinics throughout the UK.

The Group saw an incredible 226 per cent increase in the number of non-surgical procedures performed in 2008. A total of 5,200 treatments were carried out across the group last year with treatments such as Botox®, hyperhidrosis and facial peels rising in popularity.

Since The Hospital Group was established in 1992, it has grown from a small pharmaceutical company to one of the UK’s foremost cosmetic surgery providers. The Group is committed to providing the very highest standards and all procedures are performed by an expert medical team in state-of-the-art facilities that are second to none.

Via EPR Network
More Healthcare press releases

Clinics, Consultations, Cosmetic Surgery, Healthcare, Healthcare Information, Healthcare Services, Non-Surgical Procedure, Plastic Surgery, Society

Sweaty Summers A Thing Of The Past

The virtues of a colourful summer wardrobe are extolled by many a style expert. But many men and women across the UK have little choice but to reach for something in black or white – for fear of the embarrassment caused by their excessive sweating.

Sweating is a natural function to control body temperature, but for some people excessive sweating – or hyperhidrosis – can occur for no apparent reason.

The severity of the condition varies from person to person and the underarm area is usually the main area affected. Wherever the condition strikes, excessive sweating can prove problematic socially and professionally.

The condition comes about when the sympathetic nervous system, which controls involuntary responses such as sweating and blushing, fails to regulate sweating. But The Hospital Group can provide relief for those suffering from the affliction with its BOTOX® cure.

The BOTOX® treatment involves a series of injections in the affected area, which prevents the release of the chemical acetylcholine from the nerve fibres that stimulate overactive sweat glands.

The non-surgical procedure takes only half an hour and the patient will see a dramatic improvement that lasts for around six months.

The Hospital Group, one of the country’s leading cosmetic surgeries, provides a vast number of non-surgical treatments across its 19 clinics throughout the UK.

The Group saw an incredible 226 per cent increase in the number of non-surgical procedures performed in 2008. A total of 5,200 treatments were carried out across the group last year with treatments such as BOTOX®, hyperhidrosis and face peels rising in popularity.

The Hospital Group is committed to providing the very highest standards and all procedures are performed by an expert medical team in state-of-the-art facilities that are second to none. Since The Hospital Group was established, it has grown from a small pharmaceutical company to one of the UK’s foremost cosmetic surgery providers.

Via EPR Network
More Healthcare press releases